SCHEMBL30983436

SCHEMBL30983436

Cc1cc(OCCCN(C)C)ncc1-c1nc2c(OC3(C)CC3)ncnc2n1Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 3/20 0.40
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TLR7 Q9NYK1 5/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ GUCY1B2 O75343 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ DRD1 P21728 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ GUCY1A2 P33402 1/20 0.35
▸ ADRA1A P35348 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983493 0.96 PIK3CD (0.40) PIK3CDMEN1KMT2ATLR7POLB
SCHEMBL30983430 0.90 PIK3CD (0.41) PIK3CDTLR7
SCHEMBL30983607 0.89 PIK3CD (0.41) PIK3CDTLR7
SCHEMBL30983552 0.87 PIK3CD (0.40) PIK3CDTLR7HTR1ASLC6A4ADRA1A
SCHEMBL30983871 0.86 PIK3CD (0.41) PIK3CDTLR7HTR1AADRA1AKCNH2
SCHEMBL30983537 0.86 PIK3CD (0.40) PIK3CDTLR7HTR1AKCNH2
SCHEMBL30983600 0.85 TLR7 (0.44) PIK3CDMEN1KMT2ATLR7HTR1A
SCHEMBL30983394 0.85 PIK3CD (0.39) PIK3CDTLR7HTR1AADRA1AKCNH2
SCHEMBL30983453 0.84 PIK3CD (0.39) PIK3CDHTR1A
SCHEMBL30983903 0.83 PIK3CD (0.42) PIK3CDTLR7CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB PIK3CD 434/4885MEN1 3755/4885KMT2A 880/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB PIK3CD 434/4885MEN1 3755/4885KMT2A 880/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB PIK3CD 434/4885MEN1 3755/4885KMT2A 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback